Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...
The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat ...
PORTLAND, IN, UNITED STATES, January 28, 2025 /EINPresswire / -- The RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development ...
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...
The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...
Hosted on MSN3d
BTIG Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Buy RecommendationFintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy ...
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Recule, a biotechnology company pioneering RNA therapies, and GBI Biomanufacturing, a leading contract development and manufacturing organization (CDMO), today announced a strategic partnership to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback